Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor for the 
treatment of anemia of chronic kidney disease. This phase 3 study evaluated the 
efficacy and safety of daprodustat in an uncontrolled cohort of 56 Japanese 
peritoneal dialysis patients with anemia over 52 weeks. Subjects received 
daprodustat 4 mg orally once daily for 4 weeks and the dose was subsequently 
adjusted every 4 weeks. Mean baseline hemoglobin was 10.9 g/dL (95% CI 10.59, 
11.12). Mean hemoglobin reached the target range (11.0-13.0 g/dL) at week 12 and 
was maintained until week 52. Mean hemoglobin during weeks 40-52 was 12.1 g/dL 
(95% CI 12.0, 12.2). The most frequent adverse events included nasopharyngitis 
(29%), catheter-site infection (18%), peritonitis (16%), diarrhea (14%), and 
nausea (11%). No deaths were reported. Once-daily oral daprodustat treatment was 
generally well tolerated and mean hemoglobin was achieved and maintained within 
the target range in Japanese peritoneal dialysis participants.